Page 41 - GHES-1-2

Global Health Econ Sustain Fast-track drug approvals in Brazil

uncertainties in the efficacy and safety of a drug registered References
through the fast-track process, which often relies on Phase Amini, L., Silbert, S.K., Maude, S.L., Nastoupil, L.J., Ramos, C.A.,
II studies, the implementation of provisional registration Brentjens, R.J., et al. (2022). Preparing for CAR T cell therapy:
with real-world evaluation of outcomes, along with Patient selection, bridging therapies and lymphodepletion.
managed entry agreements, may present a sustainable Nature Reviews Clinical Oncology, 19:342-355.
alternative for health-care systems.
https://doi.org/10.1038/s41571-022-00607-3
Acknowledgments ANVISA. (2022a). Autorizada Pesquisa Nacional Com Células
CAR-T Para Tratar Câncer. Agência Nacional de Vigilância
None. Sanitária-anvisa. Available from: https://www.gov.br/anvisa/
Funding pt-br/assuntos/noticias-anvisa/2022/autorizada-pesquisa-
nacional-com-celulas-car-t-para-tratar-cancer-1 [Last
None. accessed on 2022 Dec 12].
Conflict of interest ANVISA. (2022b). Institucional. Agência Nacional de Vigilância
Sanitária-anvisa. Available from: https://www.gov.br/anvisa/
The authors declare that they have no competing interests. pt-br/acessoainformacao/institucional/capa-institucional
[Last accessed on 2022 Dec 12].
Author contributions Archanjo, E. (2022). Kymriah . Bulas de Medicamentos. Available
®
Conceptualization: Marcus Carvalho Borin, Mariana from: https://portal.novartis.com.br/medicamentos/
Michel Barbosa, Camila Oliveira Pereira, Silvana kymriah [Last accessed on 2022 Dec 12].
Marcia Bruschi Kelles Bootes, A., Maundu, J., Golding, S., McDonald, M., &
Investigation: Marcus Carvalho Borin, Mariana Michel Lombard, J. (2019). Fast-track pathways for drug approvals:
Barbosa, Camila Oliveira Pereira, Silvana Marcia The Australian experience so far. Australian Prescriber,
Bruschi Kelles 42:118-119.
Methodology: Marcus Carvalho Borin, Mariana Michel https://doi.org/10.18773/austprescr.2019.044
Barbosa, Carina Rejane Martins, Mariza Cristina Brasil. (2016). Lei No 13.411.
Torres Talim
Project administration: Silvana Marcia Bruschi Kelles Brasil. (2017a). Resolução RDC n° 204, de 27 de Dezembro de
2017. Brazil: Agência Nacional de Vigilância Sanitária
Supervision: Ernesto Gomes de Azevedo, Sergio Adriano (Anvisa). Available from: http://antigo.anvisa.gov.br/
Loureiro Bersan, Silvana Marcia Bruschi Kelles documents/10181/2718376/RDC_204_2017_.pdf/
Visualization: Daniel Pitchon dos Reis, Geraldo José Coelho b2d4ae64-2d91-44e9-ad67-b883c752c094 [Last accessed on
Ribeiro, Júlia Teixeira Tupinambás, Karina de Castro 2023 Apr 20].
Zocrato, Lélia Maria de Almeida Carvalho, Marcela Brasil. (2017b). Resolução RDC n° 205, de 28 de Dezembro de
Pinto de Freitas, Maria da Glória Cruvinel Horta 2017. Brazil: Agência Nacional de Vigilância Sanitária
Writing – original draft: Marcus Carvalho Borin, Mariana (Anvisa). Available from: https://bvsms.saude.gov.br/bvs/
Michel Barbosa, Silvana Marcia Bruschi Kelles saudelegis/anvisa/2017/rdc0205_28_12_2017.pdf [Last
Writing – review & editing: Marcus Carvalho Borin, accessed on 2023 Apr 20].
Mariana Michel Barbosa, Silvana Marcia Bruschi Kelles Canada, H. (2002). Priority Review of Drug Submissions
Ethics approval and consent to participate (Therapeutic Products). Available from: https://www.
canada.ca/en/health-canada/services/drugs-health-
Not applicable. products/drug-products/fact-sheets/priority-review-drug-
submissions-therapeutic-products.html [Last accessed on
Consent for publication 2022 Dec 12].

Not applicable. EMA. (2018). Accelerated Assessment. European Medicines
Agency. Available from: https://www.ema.europa.eu/en/
Availability of data human-regulatory/marketing-authorisation/accelerated-
assessment [Last accessed on 2022 Dec 12].
Data can be obtained from corresponding author following
formal request. FDA. (2018). Fast Track, Breakthrough Therapy, Accelerated
Approval, Priority Review: What Do These Terms Mean?
Further disclosure Washington, DC: U.S. Food and Drug Administration.
Available from: https://www.fda.gov/patients/fast-track-
Not applicable. breakthrough-therapy-accelerated-approval-priority-

Volume 1 Issue 2 (2023) 10 https://doi.org/10.36922/ghes.0995